Subcellular Targeting of Theranostic Radionuclides
The last decade has seen rapid growth in the use of theranostic radionuclides for the treatment and imaging of a wide range of cancers. Radionuclide therapy and imaging rely on a radiolabeled vector to specifically target cancer cells. Radionuclides that emit β particles have thus far dominated the...
Main Authors: | Bas M. Bavelaar, Boon Q. Lee, Martin R. Gill, Nadia Falzone, Katherine A. Vallis |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2018.00996/full |
Similar Items
-
Targeted Radionuclide Therapy
by: David Cheng, et al.
Published: (2011-10-01) -
Radiopharmaceuticals: From Molecular Imaging to Targeted Radionuclide Therapy
by: P. August Schubiger, et al.
Published: (2004-10-01) -
Determinants of target absorbed dose in radionuclide therapy
by: Heribert Hänscheid, et al.
Published: (2023-02-01) -
Targeting Melanin in Melanoma with Radionuclide Therapy
by: Kevin J. H. Allen, et al.
Published: (2022-08-01) -
What is the role of the bystander response in radionuclide therapies?
by: Darren eBrady, et al.
Published: (2013-08-01)